Claims for Patent: 8,247,444

Summary for Patent: 8,247,444

Title:	Anti-tumor effect of dimeric phthalide compound
Abstract:	The present invention provides for the use of a dimeric phthalide compound, the dimeric phthalide compound has broad anti-tumor activity, can directly inhibit the proliferation of tumor cells and induce cell death, but also indirectly inhibit the development of tumors by suppressing neovascularization. And further, the dimeric phthalide compound can be used alone or in combination to treat cancer, as well as in combination with chemotherapeutics to increase the efficacy of chemotherapeutics and decrease the toxicity of chemotherapeutics.
Inventor(s):	Chen; Fei (Shanghai, CN), Wang; Tao (Shanghai, CN), Wu; Yifeng (Shanghai, CN)
Assignee:	Chen; Fei (Shanghai, CN) Wang; Tao (Shanghai, CN)
Application Number:	12/523,792
Patent Claims:	1. A method of treating a subject having a tumor that is resistant to a drug, comprising: administering to a subject having a tumor that is resistant to a drug an amount of a dimeric phthalide compound having one of the following formulas (1) and (16), ##STR00018## wherein the amount of the dimeric phthalide compound is an amount effective for treating the tumor that is resistant to the drug. 2. The method of claim 1, wherein the amount of the dimeric phthalide compound is effective for directly inhibiting proliferation of tumor cells, directly inducing cell death, or indirectly inhibiting development of a tumor by suppressing tumor angiogenesis. 3. The method of claim 1, wherein the tumor that is resistant to the drug or the tumor that is resistant to apoptosis is selected from the group consisting of nonsmall-cell lung cancer, liver cancer, encephaloma, leukocythemia, carcinoma of prostate, intestine cancer, myeloma tumor, lymphoma, breast carcinoma, ovarian cancer, gastric cancer, small cell lung cancer, esophageal carcinoma, esophageal carcinoma, and sarcoma. 4. The method of claim 1, wherein the amount of the dimeric phthalide compound is effective for increasing an efficacy of chemotherapeutics, and/or decreasing toxicity of chemotherapeutics. 5. The method of claim 1, further comprising administering an anti-tumor drug. 6. The method of claim 5, wherein the anti-tumor drug includes at least one selected from the group consisting of a targeting drug, a cytotoxic drug, or a differentiation inductor. 7. The method of claim 1, wherein the subject having the drug resistant tumor is a subject that exhibits at least one of the following: (1) overexpression of P-glycoprotein (P-gp), (2) overexpression of Bcl-2, (3) overexpression of Breast Cancer Resistant Protein (BCRP), (4) overexpression of Multidrug Resistance Protein 1 (MRP1), (5) overexpression of Bcl-xL and overexpression of Glutathione S Transferase .pi. (GST-.pi.). 8. The method of claim 1, wherein the drug is at least one anti-tumor drug selected from the group consisting of a targeting drug, a cytotoxic drug and a differentiation inductor. 9. The method of claim 8, wherein the targeting drug is gifitinib, erlotinib, sorafenib or bevacizumab and the cytotoxic drug is vinblastine, anthracycline, an antibiotic or a metabolic drug. 10. The method of claim 1, wherein the amount of the dimeric phthalide compound is effective for inducing a decrease of cell mitochondria membrane potential and cell death.

Details for Patent 8,247,444

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-02-26